The correlation between CYP2D6 isoenzyme activity and haloperidol efficacy and safety profile in patients with alcohol addiction during the exacerbation of the addiction

por Sychev, Dmitry Alekseevich, Zastrozhin, Mikhail Sergeevich, Smirnov, Valery Valerieevich, Grishina, Elena Anatolievna, Savchenko, Ludmila Mikhailovna, Bryun, Evgeny Alekseevich
Publicado 2016

The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction

por Zastrozhin, Mikhail Sergeevich, Grishina, Elena Anatolievna, Ryzhikova, Kristina Anatolievna, Smirnov, Valery Valerievich, Savchenko, Ludmila Mikhailovna, Bryun, Evgeny Alekseevich, Sychev, Dmitry Alekseevich
Publicado 2017

Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder

por Zastrozhin, Mikhail Sergeevich, Grishina, Elena Anatolievna, Denisenko, Nataliya Petrovna, Skryabin, Valentin Yurievich, Markov, Dmitry Dmitrievich, Savchenko, Ludmila Mikhailovna, Bryun, Evgeny Alekseevich, Sychev, Dmitry Alekseevich
Publicado 2018

Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder

por Zastrozhin, Mikhail Sergeevich, Brodyansky, Vadim Markovich, Skryabin, Valentin Yurievich, Grishina, Elena Anatolievna, Ivashchenko, Dmitry Vladimirovich, Ryzhikova, Kristina Anatolievna, Savchenko, Ludmila Mikhaylovna, Kibitov, Alexander Olegovich, Bryun, Evgeny Alekseevich, Sychev, Dmitry Alekseevich
Publicado 2017